1.33Open1.33Pre Close0 Volume24 Open Interest7.50Strike Price0.00Turnover0.00%IV4.93%PremiumAug 16, 2024Expiry Date1.01Intrinsic Value100Multiplier-1DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma7.42Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Altimmune Stock Discussion
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet